OptiNose
OptiNose is a U.S. specialty pharmaceutical company that develops and commercializes prescription nasal treatments using its proprietary Bi-Directional Exhalation Delivery System (EDS), serving ENT/allergy specialists and chronic rhinosinusitis patients with its lead product XHANCE.
- Company typePrivate
- Founded2000
- HeadquartersOslo, Norway
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What OptiNose does
OptiNose US, Inc. is a U.S.-domiciled specialty pharmaceutical company that develops and commercializes prescription treatments for diseases managed by ear, nose, and throat (ENT) and allergy specialists, with its worldwide headquarters in Yardley, Pennsylvania. The company's core technology is its patented Bi-Directional Exhalation Delivery System (EDS), a drug-device combination platform available in liquid and powder configurations that uses patient exhalation to seal the soft palate and propel medication high and deep into the nasal passages, reaching anatomical sites beyond the nasal valve that conventional nasal sprays cannot effectively penetrate. The platform also has potential applications in nose-to-brain drug delivery for central nervous system disorders.
The company monetizes this platform primarily through direct commercialization of its lead product XHANCE (fluticasone propionate), FDA-approved in September 2017 for nasal polyps and in March 2024 for chronic sinusitis, sold through a network of seven authorized pharmaceutical wholesalers to ENT and allergy specialists with a planned expansion into primary care. A second product, ONZETRA Xsail (sumatriptan nasal powder) for acute migraine, was out-licensed to Currax Pharmaceuticals in September 2019 for commercialization in the United States, Canada, and Mexico, generating royalty and licensing revenue. The company additionally pursues technology licensing arrangements with selected pharmaceutical and biotechnology partners developing CNS, systemic, or topical nasal compounds.
OptiNose firmographics
Firmographics- Name
- OptiNose
- Legal name
- OptiNose US, Inc.
- Website
- https://optinose.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- OptiNose is a U.S. specialty pharmaceutical company that develops and commercializes prescription nasal treatments using its proprietary Bi-Directional Exhalation Delivery System (EDS), serving ENT/allergy specialists and chronic rhinosinusitis patients with its lead product XHANCE.
- Ownership category
- akta.pro rank
OptiNose industry classification
Industry- Product category
- Specialty Pharmaceuticals - Nasal Drug Delivery
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
- akta.pro secondary industries
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where OptiNose is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
OptiNose business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Operations
Revenue model
- Pharmaceutical Product Sales - XHANCE: Revenue from sales of FDA-approved prescription treatment XHANCE (fluticasone propionate) for nasal polyps and chronic sinusitis, commercialized directly by the company to ENT and allergy specialists.
- Licensing Revenue - ONZETRA: Royalty and licensing revenue from Currax Pharmaceuticals for ONZETRA Xsail (sumatriptan nasal powder) in US, Canada, and Mexico under September 2019 License Agreement.
- Technology Licensing: Optinose has entered into technology licensing arrangements with carefully selected companies developing products that may benefit from the unique Optinose delivery technology, including use by academic researchers.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
OptiNose product offering
Product offeringCore offering
OptiNose develops and commercializes prescription drug-device combination products for ear, nose, and throat conditions, built on its proprietary Bi-Directional Exhalation Delivery System (EDS). Its core product XHANCE (fluticasone propionate) is FDA-approved for nasal polyps and chronic sinusitis, while ONZETRA Xsail (sumatriptan nasal powder) for acute migraine is licensed to Currax Pharmaceuticals. The EDS platform is also licensed to other pharmaceutical partners for additional therapeutic applications.
Product overview
OptiNose is a specialty pharmaceutical company offering a portfolio of prescription nasal spray products powered by its proprietary Bi-Directional Exhalation Delivery System (EDS) technology. The core product portfolio consists of XHANCE (fluticasone propionate), an FDA-approved treatment for nasal polyps and chronic sinusitis, and ONZETRA Xsail (sumatriptan nasal powder), licensed to Currax Pharmaceuticals for migraine treatment. The EDS platform serves as the foundational technology enabling both products to deliver medication deep into nasal passages, and is also being evaluated for potential nose-to-brain drug delivery applications.
Differentiator
Problem solved
Functional benefit
Brands
- XHANCE: FDA-approved prescription treatment for nasal polyps and chronic sinusitis, delivered using OptiNose's Bi-Directional Exhalation Delivery System.
- ONZETRA Xsail
- Bi-Directional Exhalation Delivery Systems
Products and services
- XHANCE (fluticasone propionate) FDA-approved prescription nasal spray delivering fluticasone propionate deep into nasal passages via the Bi-Directional Exhalation Delivery System. Indicated for the treatment of nasal polyps in adults (since September 2017) and chronic sinusitis in adults (since March 2024). Commercialized directly by OptiNose to ENT and allergy specialists.
- ONZETRA Xsail (sumatriptan nasal powder) Low-dose sumatriptan nasal powder delivered via OptiNose's Bi-Directional Exhalation Delivery System for acute treatment of migraine with or without aura in adults. Licensed exclusively to Currax Pharmaceuticals for US, Canada, and Mexico.
- Bi-Directional Exhalation Delivery Systems (EDS) Technology Platform Proprietary drug-device delivery technology platform that uses patient exhalation to create an airtight seal of the soft palate and propel medication beyond the nasal valve into deep nasal passages. Available in liquid and powder configurations, it is licensed to selected pharmaceutical, biotechnology, and academic partners for CNS, systemic, and topical nasal applications, including potential nose-to-brain drug delivery.
Quantifiable outcome
- Significantly larger initial deposition in upper and middle posterior nasal regions compared to traditional spray (53.5% vs 15.7%, p<0.02)
- +3 more outcomes
Companies that use OptiNose
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
OptiNose technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
OptiNose partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major, minor and core.
- Currax PharmaceuticalsmajorIn September 2019, Optinose announced a License Agreement with Currax Pharmaceuticals granting exclusive rights to certain Optinose intellectual property for marketing ONZETRA Xsail (sumatriptan nasal powder) in the United States, Canada, and Mexico. This partnership enabled commercialization of the migraine treatment through Currax's existing commercial infrastructure.
- Academic ResearchersminorOptinose has allowed use of its technology by a small number of academic researchers for scientific studies and clinical trials investigating nasal drug delivery applications.
- Pharmaceutical and Biotechnology CompaniesminorOptinose has entered into technology licensing arrangements with carefully selected companies developing products that may benefit greatly from the unique Optinose delivery technology for CNS, systemic, or topical nasal compounds.
- Paratek PharmaceuticalscoreParatek acquired Optinose in March 2025 for up to $330 million ($9 per share upfront plus CVRs). The acquisition was triggered by XHANCE's 2023 FDA label expansion broadening eligible patient population 10-fold to 10 million people, enabling Paratek to commercialize the product through its existing primary care sales force.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
OptiNose competitors and assessment
Company assessmentDirect peers
- Lyra Therapeutics: Clinical-stage ENT specialty pharmaceutical company developing drug-delivery technologies for chronic rhinosinusitis and other ENT conditions. Highly comparable to OptiNose given overlapping therapeutic focus on CRS and parallel investment in novel nasal/sinus drug delivery platforms.
- ARS Pharmaceuticals: Specialty pharmaceutical company developing intranasal epinephrine (neffy) for allergic reactions. Comparable to OptiNose as a small-cap intranasal drug delivery company targeting allergy/respiratory indications with novel device-enabled formulations.
- Intersect ENT (acquired by Medtronic): Previously independent developer of steroid-eluting sinus implants (PROPEL) used by ENT surgeons in chronic rhinosinusitis patients. Directly comparable in targeting the ENT/CRS specialty prescribing base with a delivery-differentiated therapy.
- Otonomy: Specialty pharmaceutical company developing therapeutics for ear-related (otology) conditions using sustained-release drug delivery technologies. Comparable to OptiNose as a small-cap ENT-focused specialty pharma with novel drug-device combination products.
Broad incumbents
- GlaxoSmithKline (GSK): Global pharmaceutical company and leading manufacturer of over-the-counter and prescription nasal allergy sprays including Flonase (fluticasone). Broad incumbent competing with XHANCE in the same therapeutic class through established OTC and generic brands with massive distribution.
- Sanofi: Global pharmaceutical company marketing Nasacort (triamcinolone) and other respiratory/allergy products. Broad incumbent with overlapping respiratory/allergy pharmaceutical franchise that competes for the same prescription and OTC patient pool targeted by XHANCE.
- AstraZeneca: Global pharmaceutical company with Rhinocort (budesonide) and a broad respiratory/allergy portfolio including biologics for severe asthma and CRS. Comparable as a broad incumbent with deep respiratory franchise that overlaps with the chronic rhinosinusitis patient population.
- Merck & Co. Global pharmaceutical company whose respiratory portfolio includes Nasonex (mometasone) and Dulera. Broad incumbent with overlapping corticosteroid nasal spray franchise competing for the same allergy and CRS prescription patients.
- Teva Pharmaceutical Industries: Global generic and specialty pharmaceutical company producing generic fluticasone nasal sprays and other respiratory products. Broad incumbent that competes directly on price in the same fluticasone-based nasal spray market that XHANCE must differentiate against.
Emerging players
- Amphastar Pharmaceuticals: Specialty pharmaceutical company focused on injectable, inhalation, and intranasal products including generic nasal sprays. Comparable as a smaller specialty player operating in intranasal drug delivery with parallel regulatory and commercial infrastructure requirements.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
OptiNose social profiles
Digital presenceOptiNose compliance and trust
Trust signalCompliance1 record
OptiNose financial estimates
Financial estimateRevenue estimate
Valuation estimate
OptiNose leadership team
Management profileNumber of profiles
Profiles7 records
OptiNose funding detail
Funding detailFunding overview
Funding rounds10 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OptiNose M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OptiNose
What does OptiNose do?
OptiNose develops and commercializes prescription drug-device combination products for ear, nose, and throat conditions, built on its proprietary Bi-Directional Exhalation Delivery System (EDS). Its core product XHANCE (fluticasone propionate) is FDA-approved for nasal polyps and chronic sinusitis, while ONZETRA Xsail (sumatriptan nasal powder) for acute migraine is licensed to Currax Pharmaceuticals. The EDS platform is also licensed to other pharmaceutical partners for additional therapeutic applications.
Is OptiNose a public or private company?
OptiNose is a private company. It is classified as public and is currently acquired.
When was OptiNose founded?
OptiNose was founded in 2000. It employs 101 to 250 people.
Where is OptiNose based?
OptiNose is headquartered in Oslo, Norway, in the Europe region.
How does OptiNose make money?
Three revenue lines are on record. Pharmaceutical Product Sales - XHANCE is the primary driver. The others are licensing Revenue - ONZETRA and technology Licensing.
Who are OptiNose's main competitors?
Direct peers on record are Lyra Therapeutics, ARS Pharmaceuticals, Intersect ENT (acquired by Medtronic) and Otonomy. Broad incumbents are GlaxoSmithKline (GSK), Sanofi, AstraZeneca, Merck & Co. and Teva Pharmaceutical Industries. Amphastar Pharmaceuticals is listed as an emerging player.
Does OptiNose have an API?
No public API is recorded for OptiNose.
What industry is OptiNose in?
OptiNose's product category is Specialty Pharmaceuticals - Nasal Drug Delivery. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 339112 and its SIC code is 2834.